



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/998,058	11/30/2001	David W. Threadgill	421/34/2	6701

25297 7590 09/09/2003

JENKINS & WILSON, PA
3100 TOWER BLVD
SUITE 1400
DURHAM, NC 27707

EXAMINER

SAKELARIS, SALLY A

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 09/09/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/998,058	THREADGILL ET AL.	
	Examiner	Art Unit	
	Sally A Sakelaris	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 June 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-27 and 46-53 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-27 and 46-53 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>31703</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. This action is in response to the paper filed June 26, 2003. Applicants arguments presented in the response to the action sent have been fully considered but are not persuasive to overcome all grounds of rejection. All rejections not reiterated herein are hereby withdrawn. This action is non-final.

Specification

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code(For example, on pages 27 and 30). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Claim Interpretation

It should be noted that the some of the art cited in this office action is intending to relay the breadth of the claims as currently written.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-10, 15, 19-27, and 46-53 are rejected under 35 U.S.C. 102(b) as being anticipated by Diehl et al, PNAS 1997.

Diehl et al. teach a method for identifying multiple genetic loci for example, *Col2a1*, *Colla1* and *Col3a1*(page 5235) that modulate the phenotype of facial clefting in

mice. Diehl et al have performed a genome-wide search for loci contributing to susceptibility to teratogen-induced facial clefting in the mouse. AXB and BXA recombinant inbred(RI) lines derived from crosses between A/J and C57BL6/J strains were supplied by M. Nesbitt and the mice were then bred by intercrossing recombinant inbred lines and maintained in a colony at the University of Michigan(page 5232) as a renewable population of genetically diverse individuals. The reference teaches this study for identifying a genetic locus in the diploid mouse system wherein the inbred lines of the renewable population of genetically diverse individuals comprise less than about 100 strains, in one instance a BXD set of 26 RI lines is used(page 5234). Experiments were also performed using the AXB and BXA RI strains to evaluate both spontaneous and teratogen-induced clefting resulting in both visual and physiological phenotypes. The reference uses the extensive data on teratogen-induced clefting in the AXB and BXA RI lines collected previously with a genome wide collection of marker typings for these RI lines to study the effects of genetic polymorphisms segregating in the renewable population(page 5232, left column). Diehl et al. teach the resulting molecular phenotype of their mouse mutants with clefting phenotypes to include for example, eight collagen genes including an altered expression of one, *Col3a1*, which is normally expressed in the embryonic palate. The reference also teaches the method for identifying multiple genetic loci further comprising identifying two or more genetic loci that modulate the phenotype of clefting as seen on the reference's page 5235 in their explanation that in addition to *Col3a1*, two other genetic factors, *Colla1* and a cyclic nucleotide phosphodiesterase gene are located on the same chromosome and are thought to together, be possibly relevant to the role of cAMP in the etiology of cleft palate abnormalities(page 5235). Additionally,

the reference teaches the implication of the tenascin C gene, an extracellular matrix protein, and several cell-signaling molecules which have been previously implicated in clefting. Diehl et al. further teach the modulation of the clefting phenotype by a non-genetic factor that is a drug exposure and an interaction between two or more non-genetic factors that are drug exposures. The reference reports the findings of a genome-wide search for susceptibility genes for teratogen-induced clefting in the AXB and BXA set of recombinant inbred mouse strains, as they compare the results and the interaction between phenytoin(which induces cleft lip) and 6-aminonicotinamide(which induces cleft palate) and the cleft palate phenotype(abstract and page 5231). The reference also teaches the method of a non-genetic factors ability to modulate the clefting phenotype wherein the phenotype is modulated by environmental, non-genetic factors such as a fetus' exposure in utero to ethanol, trimethadione, aminopterin and retinoic acid(page 5231). Included then in these findings are the reference's teachings of the identification of an interaction among two or more non-genetic factors(both environmental and drug-like) and a genetic locus. Furthermore, as stated previously, this same identification was made among multiple genetic loci discovered in this study in addition to those gene mutations that are well known in the art that the present reference reiterates, such as *Msx1*, several *Hox* genes, retinoic acid receptor alpha locus etc,(page 5231).

Response to Arguments:

Applicants assert "that the phrase 'genetically diverse' has been misinterpreted by the Patent Office, and when used as it is disclosed in the specification of the instant application and described in applicants remarks, it is clear that the mouse lines produced by Diehl are not genetically diverse"(Pg. 9 response). Applicant is reminded that

Art Unit: 1634

limitations in the specification and within applicant's remarks are not read into the claims as limitations of the instant claims under examination. The claims as written do not require a specific amount of genetic diversity. Applicant should note that their definition of the recombinant inbred lines(ex. AXB and BXA) used in the Diehl et al. reference on page 12 of their specification; "refers to an inbred line derived from two unrelated inbred parent lines. An individual RI(ex. AXB or BXA) line has a characteristic combination of genes with a different pattern of alternative alleles at multiple loci"(Pg. 12). As a result, inherent in the recombinant inbred lines as defined by the applicant are "different patterns" and therefore an amount of genetic diversity that exists. Therefore, Diehl et al. teach "genetically diverse" individuals in their RI strains.

THE FOLLOWING ARE NEW GROUNDS OF REJECTION:

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4 are rejected under 35 U.S.C. 102(b) as being anticipated by Bellamy et al, (Human Genetics, 1991).

Bellamy et al. teach a method for identifying a genetic locus that modulates a phenotype, the method comprising:

- (a) providing a renewable population of diploid humans that are genetically diverse individuals; and
- (b) mapping the genomes of individuals within the renewable population of genetically diverse individuals that display the phenotype, whereby a genetic locus that modulates the phenotype is identified(Entire document especially pg. 345).

Bellamy et al. further teach the above method wherein the renewable human population of genetically diverse individuals comprises a panel of cell lines derived from genetically diverse individuals(Pg. 341).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 11-14 and 16-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Diehl et al. in view of Dindzans et al.(J. of Immunology, 1986) and in further view of Hedrich, Hans J.(“Genetic Monitoring, 1981).

Diehl et al. teach a method for identifying multiple genetic loci for example, *Col2a1*, *Col1a1* and *Col3a1*(page 5235) that modulate the phenotype of facial clefting in mice. Diehl et al have performed a genome-wide search for loci contributing to susceptibility to teratogen-induced facial clefting in the mouse. AXB and BXA

recombinant inbred(RI) lines derived from crosses between A/J and C57BL6/J strains were supplied by M. Nesbitt and the mice were then bred by intercrossing recombinant inbred lines and maintained in a colony at the University of Michigan(page 5232) as a renewable population of genetically diverse individuals. The reference teaches this study for identifying a genetic locus in the diploid mouse system wherein the inbred lines of the renewable population of genetically diverse individuals comprise less than about 100 strains, in one instance a BXD set of 26 RI lines is used(page 5234). Experiments were also performed using the AXB and BXA RI strains to evaluate both spontaneous and teratogen-induced clefting resulting in both visual and physiological phenotypes. The reference uses the extensive data on teratogen-induced clefting in the AXB and BXA RI lines collected previously with a genomic wide collection of marker typings for these RI lines to study the effects of genetic polymorphisms segregating in the renewable population(page 5232, left column). Diehl et al. teach the resulting molecular phenotype of their mouse mutants with clefting phenotypes to include for example, eight collagen genes including an altered expression of one, *Col3a1*, which is normally expressed in the embryonic palate. The reference also teaches the method for identifying multiple genetic loci further comprising identifying two or more genetic loci that modulate the phenotype of clefting as seen on the reference's page 5235 in their explanation that in addition to *Col3a1*, two other genetic factors, *Colla1* and a cyclic nucleotide phosphodiesterase gene are located on the same chromosome and are thought to together, be possibly relevant to the role of cAMP in the etiology of cleft palate abnormalities(page 5235). Additionally, the reference teaches the implication of the tenascin C gene, an extracellular matrix protein, and several cell-signaling molecules which have been previously implicated in

clefing. Diehl et al. further teach the modulation of the clefing phenotype by a non-genetic factor that is a drug exposure and an interaction between two or more non-genetic factors that are drug exposures. The reference reports the findings of a genome-wide search for susceptibility genes for teratogen-induced clefing in the AXB and BXA set of recombinant inbred mouse strains, as they compare the results and the interaction between phenytoin(which induces cleft lip) and 6-aminonicotinamide(which induces cleft palate) and the cleft palate phenotype(abstract and page 5231). The reference also teaches the method of a non-genetic factors ability to modulate the clefing phenotype wherein the phenotype is modulated by environmental, non-genetic factors such as a fetus' exposure in utero to ethanol, trimethadione, aminopterin and retinoic acid(page 5231). Included then in these findings are the reference's teachings of the identification of an interaction among two or more non-genetic factors(both environmental and drug-like) and a genetic locus. Furthermore, as stated previously, this same identification was made among multiple genetic loci discovered in this study in addition to those gene mutations that are well known in the art that the present reference reiterates, such as *Msx1*, several *Hox* genes, retinoic acid receptor alpha locus etc,(page 5231).

Diehl et al do not teach the derivation of the RI lines from at least 3, 4 or 8 non-recombinant parent lines or that genetically diverse individuals will be a natural by product from the use of multiple parent strains.

However, Dindzans et al. teach that multiple parents are necessary for the breeding of mice in an attempt to map genes and in the elucidation of mechanisms of genetic control. Dindzans et al. teach "the mode of inheritance of susceptibility/resistance to mouse hepatitis strain 3 (MHV)-3 being determined by typing

the set of AXB/BXA recombinant inbred (RI) strain derived from **resistant** A/J and **susceptible** C57BL/6J progenitors for susceptibility to infection as determined by the severity of live pathology”. “The strain distribution pattern for susceptibility showed a discontinuous variation: one strain was fully resistant(like A/J), four strains were fully susceptible (like C57BL/6J), and 16 strains showed an intermediate degree of susceptibility”(page 2355). Accordingly, it has been suggested that strain-dependent susceptibility to MHV-3 reflects genetically controlled immune defects rather than differences in the non-genetic, in this case viral factor. It is important to note the need for parental strain diversity that the reference teaches as “ the AXB/BXA RI strains used in these experiments were derived from susceptible (C57BL/6J) and resistant (A/J) progenitors representing extremes in disease” for the sole purpose of creating RI strains exhibiting distinct patterns of MHV-3 induced liver pathology, and a discontinuous strain distribution pattern of S/R was seen(page 2357, discussion). This reference then teaches the importance of having an “unique assortment of parental genes that are homozygous at every locus, as such strains are useful for the mapping of genes and restriction sites and in the elucidation of mechanisms of genetic control”(page 2355). The reference teaches that multiple progenitors were used to establish their population for the expected benefit that using multiple progenitors creates an “unique assortment of parental genes” which is “useful for the mapping of genes and restriction sites and in the elucidation of mechanisms of genetic control”.

Dindzans et al. do not teach the derivation of the RI lines from at least 3, 4 or 8 non-recombinant parent lines.

Hedrich teaches the organization of breeding colonies from a founding colony made up of 8-10 breeding pairs. Hedrich teaches in his Chapter on “genetic monitoring” of the mouse in biomedical research, that the organization of breeding colonies should include propagation steps consisting of three groups: “foundation colony (FC), pedigreed expansion colony (PEC), and production colonies(PC)”(Chapter 8, Page 171). Hedrich further teaches that the “foundation colony, which preserves the germline, should be of limited size” and that it may be either be built up as a single line (SL) or in a modified parallel line(MPL) system. With the SL system, Hedrich teaches that “SL colony members are usually more closely related to each other”. In contrast, Hedrich teaches that “in the MPL system e.g. three family lines are kept for four generations, each consisting of not more than 8-10 breeding pairs”(Pg. 171). The reference continues to teach that “one breeding pair of the foundation colony is selected as common ancestor, whose offspring will again give rise to three family lines” and further that, “the degree of kinship is varying from generation to generation within the cycle”. The reference teaches that this method makes “it possible to select among the lines that one which matches the original standards best”.

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have modified the identification of a genetic locus that modulates a phenotype method of Diehl et al. so as to have included the diverse population of non-recombinant, parent lines of Dindzans et al. and to have derived their breeding population from at least 3, 4, or 8 non-recombinant parent lines as taught in further view of Hedrich, not only for the expected benefit that more parents would obviously result in a more diverse progeny, but also for the expected benefit of

Art Unit: 1634

providing an additional means for furthered variation among mouse lines and for the ability taught by Hedrich of making "it possible to select among the lines that one which matches the original standards best"(Page 171).

Therefore, combining the teachings of Diehl et al. in view of Dindzans et al. and in further view of Hedrich would have been obvious at the time the invention was made.


Any inquiry concerning this communication or earlier communication from the examiner should be directed to Sally Sakelaris whose telephone number is (703) 306-0284. Alternatively, this junior examiner's primary, Jeffrey Fredman can be reached at (703) 308-6568. The examiner can normally be reached on Monday-Thursday from 7:30AM-5:00PM and Friday from 1:00PM-5:00PM.

If attempts to reach the examiners by telephone are unsuccessful, the examiners' supervisor, Gary Benzion, can be reached on (703)308-1119. The fax number for the Technology Center is (703)305-3014 or (703)305-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to Chantae Dessau whose telephone number is (703)605-1237.

Sally Sakelaris

9/8/2003


GARY BENZION, PH.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600